The first major report on medication-related osteonecrosis of the jaw (MRONJ) related to antiresorptive therapy, e.g., treatment with bisphosphonates, was published in 2003. This is a rare, but serious side effect related to the treatment with bone-strengthening agents for cancer and osteoporosis patients. The indications for treatment with antiresorptive agents are increasing both for cancer patients and osteoporosis patients. In 2020, the Swedish medical products agency, Läkemedelsverket, updated the recommendations for osteoporosis treatment. Background and clinical experience of MRONJ will be presented.
For further information regarding the event, please contact:
Se contact card above - Furqan A. Shah